These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 19687324)
1. Second-line chemotherapy for advanced urothelial cancer: because we should or because we can? Dreicer R J Clin Oncol; 2009 Sep; 27(27):4444-5. PubMed ID: 19687324 [No Abstract] [Full Text] [Related]
3. Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma. Sonpavde G; Pond GR; Fougeray R; Bellmunt J BJU Int; 2015 Jun; 115(6):854-5. PubMed ID: 25195625 [No Abstract] [Full Text] [Related]
4. Progress in treatment of advanced urothelial tract tumors. Yagoda A J Clin Oncol; 1985 Nov; 3(11):1448-50. PubMed ID: 3903061 [No Abstract] [Full Text] [Related]
5. Response and Development of Immune-Related Adverse Events in an 83-Year-Old Man With Metastatic Urothelial Cancer. Mehra KK; Petrylak DP Oncology (Williston Park); 2018 Mar; 32(3):132-6. PubMed ID: 29548069 [No Abstract] [Full Text] [Related]
6. Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. Tilgener C; Bedke J Eur Urol; 2024 Jun; 85(6):591-592. PubMed ID: 38538421 [No Abstract] [Full Text] [Related]
7. Vinflunine: a new microtubule inhibitor agent. Bennouna J; Delord JP; Campone M; Nguyen L Clin Cancer Res; 2008 Mar; 14(6):1625-32. PubMed ID: 18347163 [TBL] [Abstract][Full Text] [Related]
8. Current optimal chemotherapy for advanced urothelial cancer. Sonpavde G; Galsky MD; Hutson TE Expert Rev Anticancer Ther; 2008 Jan; 8(1):51-61. PubMed ID: 18095883 [TBL] [Abstract][Full Text] [Related]
9. Frontiers in combining immune checkpoint inhibitors for advanced urothelial cancer management. Rebhan K; Laukhtina E; Shariat SF; Gust KM Curr Opin Urol; 2020 May; 30(3):457-466. PubMed ID: 32235284 [TBL] [Abstract][Full Text] [Related]
10. [Cochrane Rapid Review: the immune checkpoint inhibitor pembrolizumab versus chemotherapy for the treatment of advanced urothelial carcinoma]. Wilborn D; Schmidt S Urologe A; 2019 Jan; 58(1):45-48. PubMed ID: 30560284 [No Abstract] [Full Text] [Related]
11. Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go. Gevaert T; Cimadamore A; Eckstein M; Scarpelli M; Lopez-Beltran A; Cheng L; Montironi R Future Oncol; 2019 Jul; 15(19):2199-2202. PubMed ID: 31213082 [No Abstract] [Full Text] [Related]
15. Re: Twardowski et al.: Phase II study of aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer: a California Cancer Consortium Trial (Urology 2010;76:923-926). Twardowski P Urology; 2012 May; 79(5):1191-2. PubMed ID: 22546405 [No Abstract] [Full Text] [Related]